Miruvor
Sign up
The short answer

What studies of GLP-1 drugs (unspecified) found

1paper on GLP-1 drugs (unspecified)
5,130patients in 1 health-record study, counted apart from trials
0randomised trials, the strongest kind of study

At a glance, by condition

Preventing long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised (very low certainty), for overall symptoms.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with GLP-1 drugs (unspecified) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. GLP-1 drugs (unspecified) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Preventing long COVID

Daily life and health overall

Overall symptoms1 study · 5,130 people took GLP-1 drugs (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised14,215 with outcome data · 12 months

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of GLP-1 drugs (unspecified) on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus. (2026) preprint

    People in the study
    14,215 with outcome data
    Dose
    —
    Outcome
    Long COVID via Long COVID diagnosis
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: average healthcare utilization rate, sex, age, race, data provider, BMI, tobacco use, medical conditions, medication use, and biomarker measurements We adjusted for the following data in our model: average healthcare utilization rate, sex, age, race, data provider, BMI, tobacco use, medical conditions
    Selection of participants
    Moderate. comparison group: SGLT2i chosen as active comparator. SGLT2is are a clinically relevant active comparator frequently used in prior evaluations of GLP therapies.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Censoring for no healthcare interactions during the 12-month follow-up; per-arm not analysed not reported. We considered an individual lost to follow-up by censoring (informative right censoring) if/when they had no healthcare interactions during the 12-month follow-up period.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus.2026 · compared with another group · 14,215 with outcome data · preprint
    Summary

    This retrospective cohort study used electronic health record data from the National Clinical Cohort Collaborative (N3C). It included 14,215 individuals with type 2 diabetes and COVID-19 diagnosed between October 1, 2021, and April 1, 2023. Of these, 5,130 were prescribed GLP medications and 9,085 were prescribed SGLT2i medications. The study compared the 12-month cumulative incidence of mortality and Long COVID (Long COVID diagnosis and probable Long COVID) between the groups. At 12 months, GLP prescription, compared with SGLT2i prescription, was associated with a lower risk of mortality (adjusted risk ratio 0.71, 95% CI 0.53 to 0.95; unadjusted risk ratio 0.44, 95% CI 0.35 to 0.55). The study did not detect a significant relationship for Long COVID diagnosis (adjusted risk ratio 1.01, 95% CI 0.80 to 1.27) or probable Long COVID (adjusted risk ratio 0.94, 95% CI 0.88 to 1.01). Side effects and withdrawals due to harms were not reported. The authors state that the limited clinical uptake of the Long COVID diagnosis code is a limitation, with the sample showing approximately 2% 12-month cumulative incidence. They also state potential exposure misclassification, limited generalizability of N3C, and possible residual confounding as limitations.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime